A Multicenter, Randomized, Double-Blind, Double-Dummy Study Of The Safety, Tolerability And Efficacy Of Celecoxib 200 Mg Twice A Day (With A 400 Mg Attack Dose) Versus Sodium Diclofenac 75 Mg Twice A Day In Subjects With Acute Low Back Pain

NCT00640432 Phase 4 COMPLETED

To evaluate the safety and efficacy of celecoxib versus sodium diclofenac in subjects with acute low back pain

Details

Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase	Phase 4
Status	COMPLETED
Enrolment	244
Start date	2003-10
Completion	2004-10

Conditions

• Low Back Pain

Interventions

• Diclofenac
• Celecoxib

Primary outcomes

• Change from baseline in patient-rated visual analogue scale (VAS) pain intensity assessment — Day 3

Countries

Brazil